A randomized phase 1b/2 trial of ABBV-916 in adults with early Alzheimer's disease. | ClinicLens
ABBV-916, an anti-amyloid immunotherapy, was evaluated in patients with early Alzheimer's disease (AD). This phase 1b/2, double-blind, placebo-controlled study consisted of two stages: multiple ascending dose (Stage A) and dose expansion (Stage B). In Stage A, patients were
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.